Advanced in B-Cell Lymphoma

Qingyuan H. Zhang

No. 628 Zhenyuan Road, 
Shenzhen, CN 
Advanced in B-Cell Lymphoma
No. 628 Zhenyuan Road, 
Shenzhen, CN 
OverviewLocationsClinical Research

Overview

Qingyuan Zhang practices in Shenzhen, China. Zhang is rated as an Advanced expert by MediFind in the treatment of B-Cell Lymphoma. Their top areas of expertise are Agranulocytosis, Breast Cancer, HER-2 Positive Breast Cancer, Pancreaticoduodenectomy, and Mastectomy.

Their clinical research consists of co-authoring 313 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 27 articles and participated in 2 clinical trials in the study of B-Cell Lymphoma.

Locations

No. 628 Zhenyuan Road, Shenzhen, 518107, China
Other Locations
150 Haping Road, Harbin, China
Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100730, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2025
Intervention Type: Drug
Study Drug: LOXO-305
Study Phase: Phase 2
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: ATG-010
Study Phase: Phase 2
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
View 2 Less Clinical Trials

313 Total Publications

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Journal: The New England journal of medicine
Published: October 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhang's expertise for a condition
ConditionClose
    View All 34 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile